A citation-based method for searching scientific literature

Theodosios D Filippatos, Vasilios G Athyros, Moses S Elisaf. Expert Opin Drug Metab Toxicol 2014
Times Cited: 34







List of co-cited articles
258 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
20

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Mika Nabeno, Fumihiko Akahoshi, Hiroyuki Kishida, Ikuko Miyaguchi, Yoshihito Tanaka, Shinichi Ishii, Takashi Kadowaki. Biochem Biophys Res Commun 2013
145
17

Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
Aris P Agouridis, Christos V Rizos, Moses S Elisaf, Theodosios D Filippatos. Rev Diabet Stud 2013
24
25

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
477
17

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
17

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
17

Combination drug treatment in obese diabetic patients.
Theodosios D Filippatos, Moses S Elisaf. World J Diabetes 2010
12
41

Effects of glucagon-like peptide-1 receptor agonists on renal function.
Theodosios D Filippatos, Moses S Elisaf. World J Diabetes 2013
48
14

Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin.
Masayuki Uchida, Yukio Ohshiba, Orie Mogami. J Pharmacol Sci 2011
54
14

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
628
14


Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
14




Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
T D Filippatos, V Tsimihodimos, M S Elisaf. Expert Opin Pharmacother 2016
24
20


Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
Ö Ljunggren, J Bolinder, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2012
137
11


Peptides derived from atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors.
Eunice C Y Li-Chan, Shih-Li Hunag, Chia-Ling Jao, Kit-Pan Ho, Kuo-Chiang Hsu. J Agric Food Chem 2012
103
11


Teneligliptin : expectations for its pleiotropic action.
Ryuichi Morishita, Hironori Nakagami. Expert Opin Pharmacother 2015
26
15

Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Yook-Hwan Noh, Hyeong-Seok Lim, Seok-Joon Jin, Mi Jo Kim, Yo Han Kim, Hye Ryoung Sung, Hee Youn Choi, Kyun-Seop Bae. Clin Ther 2012
24
16

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.
Miyako Kishimoto. Diabetes Metab Syndr Obes 2013
46
11

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
George R Lankas, Barbara Leiting, Ranabir Sinha Roy, George J Eiermann, Maria G Beconi, Tesfaye Biftu, Chi-Chung Chan, Scott Edmondson, William P Feeney, Huaibing He,[...]. Diabetes 2005
394
11

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
E J Rhee, W Y Lee, K H Yoon, S J Yoo, I K Lee, S H Baik, Y K Kim, M K Lee, K S Park, J Y Park,[...]. Diabetes Obes Metab 2010
34
11

Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
J H Shon, N Kim, S J Park, M K Oh, E Y Kim, S H Lee, Y H Kim, J G Shin. Diabetes Obes Metab 2014
13
30


Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
353
11


Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
Matthew R Weir, Irina Kline, John Xie, Robert Edwards, Keith Usiskin. Curr Med Res Opin 2014
71
11


SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
268
11

Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A DeFronzo. Am J Physiol Renal Physiol 2015
71
11


Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
634
11

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
11

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
512
11


Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
V Tsimihodimos, T D Filippatos, S Filippas-Ntekouan, M Elisaf. Curr Vasc Pharmacol 2017
17
23



Teneligliptin for the treatment of type 2 diabetes.
M Goda, T Kadowaki. Drugs Today (Barc) 2013
27
11

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Emanuele Bosi, Riccardo Paolo Camisasca, Carole Collober, Erika Rochotte, Alan J Garber. Diabetes Care 2007
330
8

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
433
8


Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
527
8

The impact of current and novel anti-diabetic therapies on cardiovascular risk.
John R Ussher, Gopinath Sutendra, Jagdip S Jaswal. Future Cardiol 2012
16
18

Estimating the population prevalence of diagnosed and undiagnosed diabetes.
Aaron Leong, Kaberi Dasgupta, Jean-Louis Chiasson, Elham Rahme. Diabetes Care 2013
30
10

SGLT2 mediates glucose reabsorption in the early proximal tubule.
Volker Vallon, Kenneth A Platt, Robyn Cunard, Jana Schroth, Jean Whaley, Scott C Thomson, Hermann Koepsell, Timo Rieg. J Am Soc Nephrol 2011
300
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.